Prevention & lipids

Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study

Eur J Prev CardiolPublished Retrospective cohort study

Authors' conclusion

Among people without pre-existing CVD, moderate-intensity statin with ezetimibe combination was superior to high-intensity statin monotherapy in preventing composite outcomes as well as each of MI and stroke. In contrast, low-intensity statin with ezetimibe combination reduced the risk of composite but not individual outcomes.

Study context

Population
People without pre-existing Cardiovascular Disease (CVD), Korean National Health Insurance Service datasetstwo 1:1 matched cohorts
Exposure
Low- or moderate-intensity statin + ezetimibe vs high-intensity statin monotherapy
Outcome
Composite of:
  • MI
  • Stroke
  • All-cause death
Methodological detailspropensity-score matched, nationwide
  • Propensity-score matched
  • Nationwide

Main finding

As reported in the abstract

Composite of MI, stroke and all-cause death
Each group vs high-intensity statin monotherapyHazard ratio (95% CI)P value
Moderate-intensity statin + ezetimibe
0.84(0.77–0.92)
P < 0.001
Low-intensity statin + ezetimibe
0.80(0.66–0.97)
P = 0.024

Observational data: associations, not effects.

Secondary outcomes

Individual outcomes (myocardial infarction (MI), stroke, all-cause death), moderate-intensity statin + ezetimibe · Moderate-intensity statin + ezetimibe vs High-intensity statin monotherapy

OutcomeHR (95% CI)P value
MI0.81 (0.71–0.94)P = 0.005
Stroke0.78 (0.65–0.93)P = 0.005
All-cause death not significantly reduced

Individual outcomes, low-intensity statin + ezetimibe

Risk of individual outcomes did not differ vs high-intensity statin monotherapy

Subgroups

Consistent effect of statin + ezetimibe across various subgroups

Original publication

Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study. Eur J Prev Cardiol. Published 26 February 2024. doi:10.1093/eurjpc/zwae081

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.